Literature DB >> 24213852

Expression of p53 family genes in urinary bladder cancer: correlation with disease aggressiveness and recurrence.

Danae Papadogianni1, Nikolaos Soulitzis, Demetrios Delakas, Demetrios A Spandidos.   

Abstract

p53 is a tumour suppressor gene with an established role in the majority of human neoplasias. Its homologues-p63 and p73-cannot be classified as tumour suppressors, since they encode isoforms with oncogenic properties as well. p63 plays a crucial role in epithelial cell differentiation and p73 is essential for neuronal cell development. The p63 and p73 expressions have been investigated in a variety of human tumours including bladder carcinomas; yet, this is the first study to simultaneously analyse the transcriptional levels of all p53 family members in bladder cancer. Using quantitative real-time polymerase chain reaction, we measured the mRNA expression of p53, p63 and p73 in 30 bladder tumours, each paired with adjacent normal tissue. All three studied genes were up-regulated in malignant specimens, p53 by 1.9-fold, p63 by threefold and p73 by twofold, respectively. Further analysis suggested that p63 and p73 act independently of p53 in the malignant bladder epithelium. Statistical analysis revealed that p63 overexpression was more frequent in recurrent bladder tumours (p = 0.045) and in older patients (p = 0.022). Papillary tumours also exhibited abnormal p63 expression (p = 0.026). Finally, p73 was up-regulated in Grade III one-site tumours (p = 0.040). Our results indicate that all p53 family members are abnormally expressed in bladder cancer but do not act synergistically. High levels of p63 correlate with non-muscle invasive tumours with frequent relapses, whereas p73 overexpression is associated with a more aggressive tumour phenotype.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24213852     DOI: 10.1007/s13277-013-1328-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  38 in total

1.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development.

Authors:  A Yang; R Schweitzer; D Sun; M Kaghad; N Walker; R T Bronson; C Tabin; A Sharpe; D Caput; C Crum; F McKeon
Journal:  Nature       Date:  1999-04-22       Impact factor: 49.962

Review 2.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Authors:  A Sigal; V Rotter
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

3.  Overexpression of the wild type p73 gene in human bladder cancer.

Authors:  A Yokomizo; M Mai; D J Tindall; L Cheng; D G Bostwick; S Naito; D I Smith; W Liu
Journal:  Oncogene       Date:  1999-02-25       Impact factor: 9.867

4.  p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma.

Authors:  Lorenzo Lo Muzio; Andrea Santarelli; Rosario Caltabiano; Corrado Rubini; Tiziana Pieramici; Lorenzo Trevisiol; Francesco Carinci; Rosalia Leonardi; Alfredo De Lillo; Salvatore Lanzafame; Pantaleo Bufo; Adriano Piattelli
Journal:  Hum Pathol       Date:  2005-02       Impact factor: 3.466

5.  Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection.

Authors:  Kimberly M Rieger-Christ; Arthur Mourtzinos; Peter J Lee; Ralph M Zagha; Jason Cain; Mark Silverman; John A Libertino; Ian C Summerhayes
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

Review 6.  p53: guardian of the genome and policeman of the oncogenes.

Authors:  Alejo Efeyan; Manuel Serrano
Journal:  Cell Cycle       Date:  2007-05-28       Impact factor: 4.534

7.  FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.

Authors:  Ashraf A Bakkar; Herve Wallerand; François Radvanyi; Jean-Baptiste Lahaye; Serge Pissard; Laure Lecerf; Jean Claude Kouyoumdjian; Claude C Abbou; Jean-Claude Pairon; Marie-Claude Jaurand; Jean-Paul Thiery; Dominique K Chopin; Sixtina Gil Diez de Medina
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

8.  Loss of p63 expression is associated with tumor progression in bladder cancer.

Authors:  Marshall J Urist; Charles J Di Como; Ming-Lan Lu; Elizabeth Charytonowicz; David Verbel; Christopher P Crum; Tan A Ince; Frank D McKeon; Carlos Cordon-Cardo
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

9.  p53-dependent apoptosis suppresses tumor growth and progression in vivo.

Authors:  H Symonds; L Krall; L Remington; M Saenz-Robles; S Lowe; T Jacks; T Van Dyke
Journal:  Cell       Date:  1994-08-26       Impact factor: 41.582

Review 10.  Evolution of functions within the p53/p63/p73 family.

Authors:  V De Laurenzi; G Melino
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

View more
  8 in total

1.  MicroRNA-1246 regulates the radio-sensitizing effect of curcumin in bladder cancer cells via activating P53.

Authors:  Ran Xu; Huabing Li; Shuiqing Wu; Jian Qu; Haiyan Yuan; Yangang Zhou; Qiong Lu
Journal:  Int Urol Nephrol       Date:  2019-06-24       Impact factor: 2.370

2.  The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients.

Authors:  Ji Hyung Hong; Kang San Roh; Sung-Suk Suh; Sukchan Lee; Sook Whan Sung; Jae Kil Park; Jae Ho Byun; Jin Hyoung Kang
Journal:  Tumour Biol       Date:  2015-06-25

3.  Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.

Authors:  Yuming Chen
Journal:  Dis Markers       Date:  2022-06-15       Impact factor: 3.464

4.  Survivin expression modulates the sensitivity of A549 lung cancer cells resistance to vincristine.

Authors:  Chengwei Zhou; Yonggang Zhu; Bin Lu; Weijun Zhao; Xiaodong Zhao
Journal:  Oncol Lett       Date:  2018-08-07       Impact factor: 2.967

Review 5.  [How do metastases of urological tumors develop?].

Authors:  M Rose; R Knüchel
Journal:  Urologe A       Date:  2014-06       Impact factor: 0.639

6.  The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells.

Authors:  Judith Heubach; Juliana Monsior; René Deenen; Günter Niegisch; Tibor Szarvas; Christian Niedworok; Wolfgang Arthur Schulz; Michèle Janine Hoffmann
Journal:  Mol Cancer       Date:  2015-05-21       Impact factor: 27.401

7.  Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer.

Authors:  Samanta Salvi; Daniele Calistri; Giorgia Gurioli; Elisa Carretta; Luigi Serra; Roberta Gunelli; Wainer Zoli; Valentina Casadio
Journal:  Int J Mol Sci       Date:  2014-07-14       Impact factor: 5.923

8.  TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53.

Authors:  Yinxiang Lv; Yanan Huo; Xican Yu; Rongrong Liu; Shufen Zhang; Xiaoxiao Zheng; Xianning Zhang
Journal:  Drug Des Devel Ther       Date:  2016-09-23       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.